Logo of biochemjBJ Latest papers and much more!
Biochem J. 2002 Sep 15; 366(Pt 3): 831–837.
PMCID: PMC1222837

The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks.


Substantial evidence indicates that the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib, a widely prescribed anti-inflammatory agent, displays anti-tumour effect by sensitizing cancer cells to apoptosis. As part of our effort to understand the mechanism by which celecoxib mediates apoptosis in androgen-independent prostate cancer cells, we investigated its effect on intracellular calcium concentration ([Ca(2+)](i)). Digital ratiometric imaging analysis indicates that exposure of PC-3 cells to celecoxib stimulates an immediate [Ca(2+)](i) rise in a dose- and time-dependent manner. Kinetic data show that this Ca(2+) signal arises from internal Ca(2+) release in conjunction with external Ca(2+) influx. Examinations of the biochemical mechanism responsible for this Ca(2+) mobilization indicate that celecoxib blocks endoplasmic reticulum (ER) Ca(2+)-ATPases. Consequently, inhibition of this Ca(2+) reuptake mechanism results in Ca(2+) mobilization from ER stores followed by capacitative calcium entry, leading to [Ca(2+)](i) elevation. In view of the important role of Ca(2+) in apoptosis regulation, this Ca(2+) perturbation may represent part of the signalling mechanism that celecoxib uses to trigger rapid apoptotic death in cancer cells. This Ca(2+)-ATPase inhibitory activity is highly specific for celecoxib, and is not noted with other COX inhibitors tested, including aspirin, ibuprofen, naproxen, rofecoxib (Vioxx), DuP697 and NS398. Moreover, it is noteworthy that this activity is also observed in many other cell lines examined, including A7r5 smooth muscle cells, NIH 3T3 fibroblast cells and Jurkat T cells. Consequently, this Ca(2+)-perturbing effect may provide a plausible link with the reported toxicities of celecoxib such as increased cardiovascular risks in long-term anti-inflammatory therapy.

Full Text

The Full Text of this article is available as a PDF (217K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hawkey CJ. COX-2 inhibitors. Lancet. 1999 Jan 23;353(9149):307–314. [PubMed]
  • DeWitt DL. Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol. 1999 Apr;55(4):625–631. [PubMed]
  • Everts B, Währborg P, Hedner T. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs. Clin Rheumatol. 2000;19(5):331–343. [PubMed]
  • Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC. Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol. 1999 May;31(5):551–557. [PubMed]
  • Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta. 2000 Mar 27;1470(2):M69–M78. [PubMed]
  • Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001 Jul;127(7):411–417. [PubMed]
  • Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998 Jan 15;58(2):362–366. [PubMed]
  • Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998 Oct 1;58(19):4245–4249. [PubMed]
  • Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):681–686. [PMC free article] [PubMed]
  • Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res. 1995 Jul 15;55(14):3110–3116. [PubMed]
  • Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol. 1996 Jul 26;52(2):237–245. [PubMed]
  • Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Ahnen DJ. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 1997 Jan 15;57(2):267–271. [PubMed]
  • Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999 Dec;5(12):1418–1423. [PubMed]
  • Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2000 Jun;105(11):1589–1594. [PMC free article] [PubMed]
  • Zhang X, Morham SG, Langenbach R, Young DA. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med. 1999 Aug 16;190(4):451–459. [PMC free article] [PubMed]
  • Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000 Apr 14;275(15):11397–11403. [PubMed]
  • Johnson AJ, song X, Hsu A, Chen C. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. Adv Enzyme Regul. 2001;41:221–235. [PubMed]
  • Marx J. Cancer research. Anti-inflammatories inhibit cancer growth--but how? Science. 2001 Jan 26;291(5504):581–582. [PubMed]
  • Hla T, Ristimäki A, Appleby S, Barriocanal JG. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci. 1993 Nov 30;696:197–204. [PubMed]
  • Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J. 1998 Sep;12(12):1063–1073. [PubMed]
  • Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst. 1998 Oct 21;90(20):1529–1536. [PubMed]
  • Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001 Oct;15(12):2057–2072. [PubMed]
  • Song Xueqin, Lin Ho-Pi, Johnson Amy J, Tseng Ping-Hui, Yang Ya-Ting, Kulp Samuel K, Chen Ching-Shih. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst. 2002 Apr 17;94(8):585–591. [PubMed]
  • Pozzan T, Rizzuto R, Volpe P, Meldolesi J. Molecular and cellular physiology of intracellular calcium stores. Physiol Rev. 1994 Jul;74(3):595–636. [PubMed]
  • Martikainen P, Kyprianou N, Tucker RW, Isaacs JT. Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res. 1991 Sep 1;51(17):4693–4700. [PubMed]
  • Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001 Aug 22;286(8):954–959. [PubMed]
  • Muscará MN, Vergnolle N, Lovren F, Triggle CR, Elliott SN, Asfaha S, Wallace JL. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol. 2000 Apr;129(7):1423–1430. [PMC free article] [PubMed]
  • Lu PJ, Gou DM, Shieh WR, Chen CS. Molecular interactions of endogenous D-myo-inositol phosphates with the intracellular D-myo-inositol 1,4,5-trisphosphate recognition site. Biochemistry. 1994 Sep 27;33(38):11586–11597. [PubMed]
  • Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985 Mar 25;260(6):3440–3450. [PubMed]
  • Lehotsky J, Raeymaekers L, Missiaen L, Wuytack F, De Smedt H, Casteels R. Stimulation of the catalytic cycle of the Ca2+ pump of porcine plasma-membranes by negatively charged phospholipids. Biochim Biophys Acta. 1992 Mar 23;1105(1):118–124. [PubMed]
  • McConnell EJ, Wagoner MJ, Keenan CE, Raess BU. Inhibition of calmodulin-stimulated (Ca2+ + Mg2+)-ATPase activity by dimethyl sulfoxide. Biochem Pharmacol. 1999 Jan 1;57(1):39–44. [PubMed]
  • Tiffert T, Lew VL. Kinetics of inhibition of the plasma membrane calcium pump by vanadate in intact human red cells. Cell Calcium. 2001 Nov;30(5):337–342. [PubMed]
  • Cobbold PH, Rink TJ. Fluorescence and bioluminescence measurement of cytoplasmic free calcium. Biochem J. 1987 Dec 1;248(2):313–328. [PMC free article] [PubMed]
  • Fowler CJ, Tiger G. Calibration of Fura-2 signals introduces errors into measurement of thrombin-stimulated calcium mobilisation in human platelets. Clin Chim Acta. 1997 Sep 30;265(2):247–261. [PubMed]
  • Putney JW., Jr A model for receptor-regulated calcium entry. Cell Calcium. 1986 Feb;7(1):1–12. [PubMed]
  • Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993 Jan 28;361(6410):315–325. [PubMed]
  • Berridge MJ, Bootman MD, Lipp P. Calcium--a life and death signal. Nature. 1998 Oct 15;395(6703):645–648. [PubMed]
  • Thastrup O, Cullen PJ, Drøbak BK, Hanley MR, Dawson AP. Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2466–2470. [PMC free article] [PubMed]
  • Worley PF, Baraban JM, Colvin JS, Snyder SH. Inositol trisphosphate receptor localization in brain: variable stoichiometry with protein kinase C. Nature. 1987 Jan 8;325(7000):159–161. [PubMed]
  • Hill TD, Berggren PO, Boynton AL. Heparin inhibits inositol trisphosphate-induced calcium release from permeabilized rat liver cells. Biochem Biophys Res Commun. 1987 Dec 31;149(3):897–901. [PubMed]
  • Chamberlain BK, Volpe P, Fleischer S. Inhibition of calcium-induced calcium release from purified cardiac sarcoplasmic reticulum vesicles. J Biol Chem. 1984 Jun 25;259(12):7547–7553. [PubMed]
  • Molinari M, Carafoli E. Calpain: a cytosolic proteinase active at the membranes. J Membr Biol. 1997 Mar 1;156(1):1–8. [PubMed]
  • Neamati N, Fernandez A, Wright S, Kiefer J, McConkey DJ. Degradation of lamin B1 precedes oligonucleosomal DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei. J Immunol. 1995 Apr 15;154(8):3788–3795. [PubMed]
  • Poenie M, Tsien RY, Schmitt-Verhulst AM. Sequential activation and lethal hit measured by [Ca2+]i in individual cytolytic T cells and targets. EMBO J. 1987 Aug;6(8):2223–2232. [PMC free article] [PubMed]
  • McConkey DJ, Nicotera P, Hartzell P, Bellomo G, Wyllie AH, Orrenius S. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca2+ concentration. Arch Biochem Biophys. 1989 Feb 15;269(1):365–370. [PubMed]
  • Yakovlev AG, Wang G, Stoica BA, Boulares HA, Spoonde AY, Yoshihara K, Smulson ME. A role of the Ca2+/Mg2+-dependent endonuclease in apoptosis and its inhibition by Poly(ADP-ribose) polymerase. J Biol Chem. 2000 Jul 14;275(28):21302–21308. [PubMed]
  • Wertz IE, Dixit VM. Characterization of calcium release-activated apoptosis of LNCaP prostate cancer cells. J Biol Chem. 2000 Apr 14;275(15):11470–11477. [PubMed]
  • Asai A, Qiu J h, Narita Y, Chi S, Saito N, Shinoura N, Hamada H, Kuchino Y, Kirino T. High level calcineurin activity predisposes neuronal cells to apoptosis. J Biol Chem. 1999 Nov 26;274(48):34450–34458. [PubMed]
  • Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate. 2000 Jun 1;43(4):303–317. [PubMed]
  • Pacher P, Hajnóczky G. Propagation of the apoptotic signal by mitochondrial waves. EMBO J. 2001 Aug 1;20(15):4107–4121. [PMC free article] [PubMed]
  • Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res. 1994 Dec 1;54(23):6167–6175. [PubMed]
  • Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Doody LA, Malone WF, Hawk ET, Sigman CC. New agents for cancer chemoprevention. J Cell Biochem Suppl. 1996;26:1–28. [PubMed]
  • Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett. 2001 Oct 30;172(2):111–118. [PubMed]
  • Bilmen JG, Khan SZ, Javed MH, Michelangeli F. Inhibition of the SERCA Ca2+ pumps by curcumin. Curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP. Eur J Biochem. 2001 Dec;268(23):6318–6327. [PubMed]
  • Logan-Smith MJ, Lockyer PJ, East JM, Lee AG. Curcumin, a molecule that inhibits the Ca2+-ATPase of sarcoplasmic reticulum but increases the rate of accumulation of Ca2+. J Biol Chem. 2001 Dec 14;276(50):46905–46911. [PubMed]
  • Dyer JL, Khan S Zafar, Bilmen JG, Hawtin SR, Wheatley M, Javed M-ul-H, Michelangeli F. Curcumin: a new cell-permeant inhibitor of the inositol 1,4,5-trisphosphate receptor. Cell Calcium. 2002 Jan;31(1):45–52. [PubMed]
  • Cheng Yan, Austin Sandra C, Rocca Bianca, Koller Beverly H, Coffman Thomas M, Grosser Tilo, Lawson John A, FitzGerald Garret A. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002 Apr 19;296(5567):539–541. [PubMed]
  • Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000 Mar;38(3):225–242. [PubMed]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...